LICENSE AGREEMENTLicense Agreement • April 14th, 2010 • Peregrine Pharmaceuticals Inc • In vitro & in vivo diagnostic substances
PEREGRINE PHARMACEUTICALS INC, (formerly known as TECHNICLONE CORPORATION) of 14282 Franklin Avenue, Tustin, CA 92780-7017, USA (hereinafter referred to as "Licensee")
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • April 14th, 2010 • Peregrine Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • California
THIS COMMERCIAL LICENSE AGREEMENT (this "Agreement") is entered into as of the 1st day of December, 2003 by and between Avanir Pharmaceuticals, a California corporation ("Avanir"), and Peregrine Pharmaceuticals, Inc., a Delaware corporation ("Peregrine").
NON-EXCLUSIVE CABILLY PATENT LICENSE AGREEMENTNon-Exclusive Patent License Agreement • April 14th, 2010 • Peregrine Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • California
This Non-Exclusive Cabilly Patent License Agreement ("Agreement") is effective as of November 5, 2003 ("Effective Date") by and between Genentech, Inc., a Delaware corporation having its principal place of business at 1 DNA Way, South San Francisco, CA 94080 (hereinafter "Genentech") and Peregrine Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 14272 Franklin Ave, Suite 100, Tustin, CA 92780 (hereinafter "Licensee").
EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • April 14th, 2010 • Peregrine Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • Texas
AMENDMENT No. 1 TO EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • April 14th, 2010 • Peregrine Pharmaceuticals Inc • In vitro & in vivo diagnostic substances
This Amendment No. 1 to Exclusive Patent License Agreement (AMENDMENT ONE) is made and entered into as of June 1, 2009 by and between Peregrine Pharmaceuticals, Inc. (LICENSEE) and the Board of Regents (BOARD) of The University of Texas System (SYSTEM).
AMENDMENT No. 1 TO EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • April 14th, 2010 • Peregrine Pharmaceuticals Inc • In vitro & in vivo diagnostic substances
This Amendment No. 1 to Exclusive Patent License Agreement (AMENDMENT ONE) is made and entered into as of June 1, 2009 by and between Peregrine Pharmaceuticals, Inc. (LICENSEE) and the Board of Regents (BOARD) of The University of Texas System (SYSTEM).
EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • April 14th, 2010 • Peregrine Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • Texas
THIS Agreement (AGREEMENT) is between the Board of Regents (BOARD) of The University of Texas System (SYSTEM), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of the University of Texas Southwestern Medical Center at Dallas (UT SOUTHWESTERN), a component institution of SYSTEM, and Peregrine Pharmaceuticals, Inc. (LICENSEE), a Delaware corporation having a principal place of business located at 14272 Franklin Avenue, Suite 100, Tustin, California 92780.
